Table 5.
HPLC-MS analyses of the active desert actinobacterial strain
| Strains | Thin Layer Chromatography (TLC) Profile | HPLC-Retention time (tR/min) | (+) and (−)-ESI-MS: (m/z) | Molecular Weights | Activity against MRSA | Suggested Streptomyces metabolites from AntiBase 2017 (Additional files 15 and 20) |
||
|---|---|---|---|---|---|---|---|---|
| UV Visualization | Staining with Anisaldehyde/H2SO4 | |||||||
| AFD2 | 254 nm | 4 bands | 2green, 1purple, 2yellow |
6.38 11.03 12.57 |
113 [M + H]+, 111[M-H]− 208 [M + H]+, 206 [M-H]− 137 [M + H]+, 135 [M-H]− |
112 207 136 |
17 mm zone of inhibition against MRSA A5;32 mm zone of inhibition against MRSA A11 | MW = 112: Emimycin, 3,5-Dimethyl-3-oxol-2-on, Uracil, Enimycin. MW = 207: Triacsin C, Triacsin D, Streptazolin, 2-(2-Hydroxypropionyl)acetanilide, Aeruginol, 7-Deoxyechinosporin. MW = 136: Pyrrole-3-yl-2-propenamide, Anthranilamide, Octalactin C. |
| 366 nm | 2 bands | |||||||
| AFD4 | 254 nm | 3 bands | 2 purple bands, 1 light blue band, 1 yellow band, 1 green band | 10.23 12.22 12.60 |
211 [M + H]+, 209 [M-H]− 146 [M + H]+ 137 [M + H]+, 135 [M-H]− |
210 145 136 |
9 mm zone of inhibition against MRSA A11;18 mm zone of inhibition against MRSA A5 | MW = 210: 1-Methoxyphenazine, 1-Acetyl-β-carboline MW = 146: Indole-3-carbaldehyde MW = 136: Pyrrole-3-yl-2-propenamide, Anthranilamide, Octalactin C. |
| 366 nm | 2 bands | |||||||
| AFD7 | 254 nm | 4 bands | 2 green bands, 2 yellow bands, 1 blue band | 3.83 4.50 5.77 7.10 10.24 11.07 11.38 11.91 13.16 15.05 16.72 |
153 [M + H]+, 151 [M-H]− 202 [M + H]+ 261 [M + H]+, 259 [M-H]− 115 [M + H]+, 113 [M-H]− 211 [M + H]+ 145 [M + H]+, 143 [M-H]− 424 [M + H]+, 422 [M-H]− 407 [M + H]+, 405 [M-H]− 494 [M + H]+ 231 [M + H]+, 229 [M-H]− 390 [M + H]+, 388 [M-H]− 223 [M + H]+, 245 [M + Na]+ |
152 201 260 114 210 144 423 406 493 230 389 222 |
20 mm zone of inhibition against MRSA A11; 25 mm zone of inhibition against MRSA A7 | MW = 152: Guanazolo, Orsellin-aldehyde, MY3–469, Xanthine. MW = 260: Cyclo(L-Tyr-L-Pro), VibrindoleA MW = 114: 4-Hydroxy-5-methyl-furan-3-one MW = 210: 1-Methoxyphenazine, 1-Acetyl-β-carboline MW = 144: Pentenomycin I, 4-Epipentenomycin I MW = 423: Fibrostatin B, A9145 A, 6-Amino-9 [(aminocarbonyl)amino]-1-(6-amino-9H-purin-9-yl)-1,5,6,7,8,9- hexadeoxy-decafuranuronamide MW = 389: Hatomamicin, SF-2809-I |
| 366 nm | 4 bands | |||||||
| AFD8 | 254 nm | 4 bands | 4 blue bands | 9.07 13.42 14.94 15.58 |
153 [M + H]+, 151 [M-H]− 257 [M + H]+, 255 [M-H]− 225 [M + H]+ 181 [M + H]+ |
152 256 224 180 |
12 mm zone of inhibition against MRSA A12;17 mm zone of inhibition against MRSA A1 | MW = 152: o Hydroxyphenylacetic acid, BE-39907 A2 MW = 256: Phenacein, Albonoursin, N-Isobutyrylpyrrothine, 2,9-Dihydroxyphenazine-1-carboxylic acid |
| 366 nm | 3 bands | |||||||
| AFD10 | 254 nm | 4 bands | 3 yellow bands, 2 brown bands | 9.90 12.60 15.61 19.42 |
211 [M + H]+ 137 [M + H]+,135 [M-H]− 401 [M + H]+, 399 [M-H]− 475 [M + H]+, 473 [M-H]− |
210 136 400 474 |
17 mm zone of inhibition against MRSA A7; 20 mm zone of inhibition against MRSA A2 | MW = 210: 1-Methoxyphenazine, 1-Acetyl-β-carboline. MW = 136: Pyrrole-3-yl-2-propenamide, Anthranilamide, Octalactin C. MW = 400: Daunomycinol, Furaquinocin G, Daidzein-7-α-l-rhamnoside, Oxopropaline-E, 2 11-A. MW = 474: N-Ethyloxytetracycline, KS-619-1. |
| 366 nm | 1 band | |||||||
| AFD12 | 254 nm | 3 bands | 1 dark yellow band, 1 pink band, 1 green band | 3.70 4.36 6.43 12.50 16.06 |
- 160 [M + H]+,158 [M-H]− 110 [M-H]− 205 [M-H]− 137 [M + H]+, 135 [M-H]− 211 [M + H]+ |
- 159 111 206 136 210 |
11 mm zone of inhibition against MRSA A7; 15 mm zone of inhibition against MRSA A5 | MW = 159: 4-(Hydroxymethyl)quinolone, Quinazolinamine MW = 136: Pyrrole-3-yl-2-propenamide, Anthranilamide, Octalactin C. MW = 210: Nikkomycin E, (4R)-Thiolactomycin, Cyanomycin, 2-Amino-4-hydroxy-3-methyl-4-(3-pyridyl)butanoic acid. |
| 366 nm | 2 bands | |||||||
| AFD26 | 254 nm | 4 bands | 1 brown bands, 1 purple band, 1 light blue band, 1 greenish blue band | .48 6.32 6.38 9.49 10.85 12.23 17.43 |
1052 [M + H]+?? 113 [M + H]+, 111 [M-H]− 164 [M + H]+, 162 [M-H]− 164 [M + H]+, 162 [M-H]− 164 [M + H]+, 162 [M-H]− 317 [M + H]+ 391 [M + H]+ |
112 163 163 163 316 390 |
10 mm zone of inhibition against MRSA A1; 15 mm zone of inhibition against MRSA A7 | MW = 112: Emimycin, 3,5-Dimethyl-3-oxol-2-on, Uracil, Enimycin. MW = 163: L-β-(3-Hydroxyureido)-alanine, Homoalanosine, β-Phenylethylacetamide, 2-N-Hydroxy-3,4-dihydroisoquinoline-1-one, Streptazone D, 2-Amino-4-hydroxy-pterin, 6-Hydroxy-isatin, Dihydroabikoviromycin, 3-Nitro-1H-indazole, Kitasatodine MW = 316: 17927-D, Boxazomycin A, 1 Isobutyroxymethyl cyclohex-1(6)-ene-2,3,4,5-tetrol-2-isobutyrate. MW = 390: SF-2330, Arizonin C3. |
| 366 nm | 2 bands | |||||||
For details, see Supplementary Information (Figure S3-S20)